ResMed, Inc.

Equities

RMD

US7611521078

Market Closed - Nyse Other stock markets 21:00:02 06/02/2026 GMT			5-day change	1st Jan Change
271.63 ^USD	+1.72%		+5.16%	+12.77%

02-06	Resmed Insider Sold Shares Worth $502,620, According to a Recent SEC Filing	MT
02-06	ResMed Chief Legal Officer Sells 50 Common Shares Of Firm	MT

Transcript : ResMed Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 10

Published on 01/12/2026 at 07:50 pm GMT - Modified on 01/13/2026 at 12:01 am GMT

S&P Capital IQ

Presenter Speech
Chris Cooper (Analysts)

Okay. Good morning, and welcome again to the JPMorgan Healthcare Conference. My name is Chris Cooper. I cover the Australian health care stocks here at

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about ResMed, Inc.

02-06	Resmed Insider Sold Shares Worth $502,620, According to a Recent SEC Filing	MT
02-06	ResMed Chief Legal Officer Sells 50 Common Shares Of Firm	MT
02-06	ResMed Director Sells 2,000 Shares	MT
02-06	ASX Biggest Gainers	MT
02-05	ASX Biggest Gainers	MT
02-03	Resmed Insider Sold Shares Worth $257,030, According to a Recent SEC Filing	MT
02-03	Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge	RE
02-02	America's New Gold Rush (and Why It Just Face-Planted)
02-02	Morgans Financial Upgrades ResMed to Buy from Accumulate, Price Target is AU$47.73	MT
02-02	Analyst recommendations: Apple, Autodesk, Best Buy, Caterpillar, PayPal…
01-30	Sector Update: Health Care Stocks Fall Premarket Friday	MT
01-30	Sector Update: Health Care	MT
01-30	RBC Raises Price Target on ResMed to $314 From $311, Keeps Outperform Rating	MT
01-30	Wolfe Adjusts Price Target on ResMed to $230 From $225, Maintains Underperform Rating	MT
01-30	Wells Fargo Adjusts Price Target on ResMed to $270 From $265, Maintains Equalweight Rating	MT
01-30	KeyBanc Adjusts Price Target on ResMed to $302 From $299, Maintains Overweight Rating	MT
01-30	Stifel Adjusts Price Target on ResMed to $265 From $260, Maintains Hold Rating	MT
01-30	Jefferies Adjusts Price Target on ResMed to $290 From $285, Maintains Hold Rating	MT
01-30	Citigroup Adjusts Price Target on ResMed to $345 From $330, Maintains Buy Rating	MT
01-30	Baird Adjusts Price Target on ResMed to $281 From $275, Maintains Neutral Rating	MT
01-30	Piper Sandler Adjusts Price Target on ResMed to $275 From $270, Maintains Neutral Rating	MT
01-30	Top Premarket Gainers	MT
01-30	Malaysia, Singapore Finalizing 'Master Plan' for Investment Hub as Billions Pour In	DJ
01-30	ResMed Inc., Q2 2026 Earnings Call, Jan 29, 2026
01-29	ResMed Posts Higher Fiscal Q2 Non-GAAP Earnings, Revenue	MT